Literature DB >> 21272568

Plasma YKL-40 levels in healthy subjects from the general population.

Stig E Bojesen1, Julia S Johansen, Børge G Nordestgaard.   

Abstract

BACKGROUND: Plasma YKL-40 is a new biomarker in patients with cancer and inflammatory diseases. High plasma YKL-40 is associated with poor prognosis. Our aim was to determine reference levels in healthy subjects.
METHODS: Plasma YKL-40 was determined in 3130 participants aged 20-80 years from the Danish general population, the Copenhagen City Heart Study. They had no known disease at time of blood sampling in 1991-1994 and remained healthy and alive during a 16-year follow-up period. In 644 participants, YKL-40 was measured again in samples taken 10 years after the first.
RESULTS: The median plasma YKL-40 was 40 μg/L (2.5-97.5% reference levels: 14-155) with no difference between sexes. YKL-40 increased exponentially with age. For age-adjusted reference levels, the YKL-40 percentile as a function of age in years and plasma YKL-40 in μg/L was derived: percentile=100/(1+(YKL-40^-3)*(1.062^age)*5000). In subjects with two YKL-40 measurements 10 years apart, the mean increase in YKL-40 was 1.5 μg/L/year (SE: 0.2), while the mean change in the calculated age percentile was minimal (-0.3; SE: 0.1).
CONCLUSIONS: Plasma YKL-40 increases with age within and across healthy individuals from the general population. Age-stratified or age-adjusted reference levels are important when YKL-40 test results are evaluated.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272568     DOI: 10.1016/j.cca.2011.01.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  38 in total

1.  Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome.

Authors:  K Türkyılmaz; V Öner; A Kırbas; M S Sevim; B Sekeryapan; G Özgür; M Durmus
Journal:  Eye (Lond)       Date:  2013-05-10       Impact factor: 3.775

2.  Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease.

Authors:  Shu-Hsin Lee; Ching-Yi Lin; Po-Hui Wang; Chih-Ping Han; Shun-Fa Yang; Jinghua Tsai Chang; Meng-Chih Lee; Long-Yau Lin; Maw-Sheng Lee
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

3.  Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function.

Authors:  Insa M Schmidt; Isaac E Hall; Sujata Kale; Sik Lee; Chuan-Hua He; Yashang Lee; Geoffrey L Chupp; Gilbert W Moeckel; Chun Geun Lee; Jack A Elias; Chirag R Parikh; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 10.121

4.  Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease.

Authors:  Yang Zhou; Chuan Hua He; Erica L Herzog; Xueyan Peng; Chang-Min Lee; Tung H Nguyen; Mridu Gulati; Bernadette R Gochuico; William A Gahl; Martin L Slade; Chun Geun Lee; Jack A Elias
Journal:  J Clin Invest       Date:  2015-06-29       Impact factor: 14.808

5.  Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis.

Authors:  Maria Kazakova; Anastas Batalov; Tanya Deneva; Nonka Mateva; Zlatimir Kolarov; Victoria Sarafian
Journal:  Rheumatol Int       Date:  2012-03-27       Impact factor: 2.631

6.  Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40.

Authors:  Jose L Gomez; Gina M Crisafi; Carole T Holm; Deborah A Meyers; Gregory A Hawkins; Eugene R Bleecker; Nizar Jarjour; Lauren Cohn; Geoffrey L Chupp
Journal:  J Allergy Clin Immunol       Date:  2015-01-13       Impact factor: 10.793

7.  Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.

Authors:  Xiaomei Liu; Yinxu Zhang; Zhitu Zhu; Minwen Ha; Yu Wang
Journal:  Med Oncol       Date:  2014-07-05       Impact factor: 3.064

8.  Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease.

Authors:  Xue Xu; Hongling Ma; Jia Xu; Haiwei Huang; Xiaohong Wu; Yan Xiong; Hong Zhan; Fan Huang
Journal:  Bosn J Basic Med Sci       Date:  2014-08-14       Impact factor: 3.363

9.  YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.

Authors:  B Kornblit; T Wang; S J Lee; S R Spellman; X Zhu; K Fleischhauer; C Müller; M R Verneris; K Müller; J S Johansen; L Vindelov; P Garred
Journal:  Bone Marrow Transplant       Date:  2016-07-18       Impact factor: 5.483

10.  Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis.

Authors:  Norihisa Nishimura; Davide De Battista; David R McGivern; Ronald E Engle; Ashley Tice; Rafaelle Fares-Gusmao; Juraj Kabat; Anna Pomerenke; Hanh Nguyen; Shinya Sato; Kevin W Bock; Ian N Moore; David E Kleiner; Fausto Zamboni; Harvey J Alter; Sugantha Govindarajan; Patrizia Farci
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.